Epsiode 3: How Ketamine, Psilocybin, MDMA Rewire the Brain for Mental Health
Tim Schlidt is the co-founder of psychedelic-focused VC fund Palo Santo. He is one of the leading voices pushing for the development of psychedelic-backed mental health therapies and has deployed over $25 million into 20 companies. Schlidt is also pushing for the FDA approval of psychedelic-assisted therapies to make them more accessible, affordable, and safe for patients suffering from treatment-resistant depression.
In this episode of Hone In, host Saad Alam sat down with him to talk about:
- How psychedelics literally rewire your brain by promoting neuroplasticity
- The anti-inflammatory and longevity benefits of psychedelics
- How MDMA and psilocybin are being used to treat PTSD and treatment-resistant depression
- Why psychedelics could yield better results than SSRIs
- When to expect FDA approval of psychedelic therapies
- How much psychedelic-assisted therapy costs